Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$48.29 +0.7%	$51.59	$21.34 ▼ $58.40	$3.86B	-0.28	1.41 million shs	534,807 shs
GMAB Genmab A/S	$24.42 +1.5%	$21.87	$17.24 ▼ $27.94	$15.67B	0.95	1.44 million shs	2.12 million shs
QGEN QIAGEN	$49.13 -0.1%	$48.53	$37.63 ▼ $51.88	$10.92B	0.64	1.37 million shs	695,538 shs
RDY Dr. Reddy's Laboratories	$14.40 +1.9%	$14.66	$12.26 ▼ $16.77	$12.02B	0.29	1.85 million shs	1.65 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+0.74%	-0.75%	-6.68%	-2.08%	+79.32%
GMAB Genmab A/S	+1.01%	+6.13%	+10.93%	+14.41%	-11.51%
QGEN QIAGEN	+0.13%	-0.06%	+2.42%	+16.30%	+7.78%
RDY Dr. Reddy's Laboratories	-0.28%	-0.87%	-2.95%	-1.04%	-15.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.9772 of 5 stars	3.5	2.0	0.0	4.7	3.5	0.8	0.0
GMAB Genmab A/S	3.8254 of 5 stars	3.3	4.0	0.0	0.0	3.2	0.0	3.1
QGEN QIAGEN	3.7578 of 5 stars	1.1	2.0	1.7	4.5	3.4	1.7	1.9
RDY Dr. Reddy's Laboratories	3.0457 of 5 stars	2.4	4.0	1.7	0.0	3.2	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$81.57	68.92% Upside
GMAB Genmab A/S	2.64	Moderate Buy	$37.60	53.97% Upside
QGEN QIAGEN	2.27	Hold	$49.69	1.12% Upside
RDY Dr. Reddy's Laboratories	2.80	Moderate Buy	$16.95	17.72% Upside

Current Analyst Ratings Breakdown

Latest AKRO, GMAB, RDY, and QGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	GMAB Genmab A/S	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
8/15/2025	RDY Dr. Reddy's Laboratories	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2025	QGEN QIAGEN	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/7/2025	QGEN QIAGEN	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$48.00 ➝ $50.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
6/26/2025	QGEN QIAGEN	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $53.00
6/24/2025	QGEN QIAGEN	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
6/5/2025	RDY Dr. Reddy's Laboratories	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$12.82 per share	N/A
GMAB Genmab A/S	$3.12B	5.02	$1.55 per share	15.71	$8.26 per share	2.96
QGEN QIAGEN	$1.98B	5.52	$3.20 per share	15.35	$15.77 per share	3.12
RDY Dr. Reddy's Laboratories	$3.81B	3.15	$1.05 per share	13.73	$4.94 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	N/A
GMAB Genmab A/S	$1.14B	$1.99	12.27	13.72	6.91	37.53%	21.03%	16.98%	11/5/2025 (Estimated)
QGEN QIAGEN	$83.59M	$1.69	29.03	19.97	2.58	18.30%	14.77%	8.87%	11/5/2025 (Estimated)
RDY Dr. Reddy's Laboratories	$663M	$0.66	21.82	17.56	5.71	16.99%	17.25%	11.63%	11/4/2025 (Estimated)

Latest AKRO, GMAB, RDY, and QGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
8/5/2025	Q2 2025	QGEN QIAGEN	$0.60	$0.60	N/A	$0.44	$523.97 million	$533.54 million
7/23/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.18	$0.20	+$0.02	$0.20	$88.27 billion	$988.82 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
QGEN QIAGEN	$0.25	0.51%	N/A	14.79%	N/A
RDY Dr. Reddy's Laboratories	$0.07	0.49%	N/A	10.61%	N/A

Latest AKRO, GMAB, RDY, and QGEN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/1/2025	QGEN QIAGEN		$0.25	0.52%	7/2/2025	7/3/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.02	12.66	12.66
GMAB Genmab A/S	N/A	6.22	6.20
QGEN QIAGEN	0.25	1.61	1.35
RDY Dr. Reddy's Laboratories	0.01	1.89	1.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
GMAB Genmab A/S	7.07%
QGEN QIAGEN	70.00%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
GMAB Genmab A/S	1.54%
QGEN QIAGEN	9.00%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
QGEN QIAGEN	5,765	222.29 million	202.29 million	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.90 million	818.20 million	Optionable

AKRO, GMAB, RDY, and QGEN Headlines

Recent News About These Companies

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 21 at 8:26 AM | marketbeat.com

Corient IA LLC Acquires New Holdings in Dr. Reddy's Laboratories Ltd $RDY

August 20 at 6:33 AM | marketbeat.com

Vestmark Advisory Solutions Inc. Increases Stock Holdings in Dr. Reddy's Laboratories Ltd $RDY

August 20 at 5:10 AM | marketbeat.com

Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

August 18 at 8:16 AM | globenewswire.com

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Bought by National Bank of Canada FI

August 18 at 3:56 AM | marketbeat.com

Zacks Research Has Optimistic Outlook of RDY Q1 Earnings

August 16, 2025 | marketbeat.com

Zacks Research Has Pessimistic Outlook of RDY Q2 Earnings

August 15, 2025 | marketbeat.com

21,345 Shares in Dr. Reddy's Laboratories Ltd (NYSE:RDY) Purchased by LGT Group Foundation

August 15, 2025 | marketbeat.com

Triglav Skladi D.O.O. Takes $857,000 Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)

August 14, 2025 | marketbeat.com

AIA Group Ltd Sells 101,293 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)

August 14, 2025 | marketbeat.com

Q2 EPS Forecast for Dr. Reddy's Laboratories Cut by Analyst

August 14, 2025 | americanbankingnews.com

Dr. Reddy’s Laboratories to Engage in Virtual Investor Conference on August 21, 2025

August 13, 2025 | msn.com

Natixis Advisors LLC Trims Stock Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)

August 13, 2025 | marketbeat.com

Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval

August 12, 2025 | theglobeandmail.com

Critical Review: Dr. Reddy's Laboratories (NYSE:RDY) vs. Targeted Medical Pharma (OTCMKTS:TRGM)

August 11, 2025 | americanbankingnews.com

Dr. Reddy's Laboratories (NYSE:RDY) vs. Aspen Pharmacare (OTCMKTS:APNHY) Head-To-Head Survey

August 10, 2025 | americanbankingnews.com

XY Capital Ltd Sells 47,520 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)

August 9, 2025 | marketbeat.com

US Bancorp DE Has $2.15 Million Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)

August 9, 2025 | marketbeat.com

Pinpoint Asset Management Ltd Reduces Position in Dr. Reddy's Laboratories Ltd (NYSE:RDY)

August 8, 2025 | marketbeat.com

Envestnet Asset Management Inc. Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd (NYSE:RDY)

August 7, 2025 | marketbeat.com

Dr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New Revenues

August 4, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKRO, GMAB, RDY, and QGEN Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$48.29 +0.34 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$49.00 +0.70 (+1.46%)

As of 04:52 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Genmab A/S NASDAQ:GMAB

$24.42 +0.36 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$24.42 +0.00 (+0.02%)

As of 06:06 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

QIAGEN NYSE:QGEN

$49.13 -0.07 (-0.13%)

Closing price 03:59 PM Eastern

Extended Trading

$49.14 +0.00 (+0.00%)

As of 04:20 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Dr. Reddy's Laboratories NYSE:RDY

$14.40 +0.27 (+1.90%)

Closing price 03:59 PM Eastern

Extended Trading

$14.45 +0.05 (+0.37%)

As of 06:30 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time